Published in Biol Psychiatry on July 15, 1994
Effects of perceived control and cognitive coping on endocrine stress responses to pharmacological activation. Biol Psychiatry (2008) 0.94
Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci (1997) 0.88
Cholecystokinin hyperresponsiveness in functional dyspepsia. World J Gastroenterol (2006) 0.87
Can Interoception Improve the Pragmatic Search for Biomarkers in Psychiatry? Front Psychiatry (2016) 0.83
Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations. J Psychiatry Neurosci (2000) 0.78
Delayed increase in LDL cholesterol following pentagastrin-induced panic attacks. Psychopharmacology (Berl) (2007) 0.76
Pentagastrin-induced release of free fatty acids in healthy volunteers and patients with panic disorder: effect of pretreatment with ethinyl estradiol. J Psychiatry Neurosci (2003) 0.75
Effect of time of preparation on pentagastrin-induced symptom, endocrine and cardiovascular responses. Psychiatry Res (2008) 0.75
Thyrotropin-releasing hormone: a potential comparator for the panicogenic effects of pentagastrin and CCK? Biol Psychiatry (1996) 0.75
The dawn of Darwinian medicine. Q Rev Biol (1991) 2.35
Marital quality and psychological adjustment to widowhood among older adults: a longitudinal analysis. J Gerontol B Psychol Sci Soc Sci (2000) 1.51
Childhood adversity and vulnerability to mood and anxiety disorders. Depress Anxiety (1997) 1.27
Persistent respiratory irregularity in patients with panic disorder. Biol Psychiatry (2001) 1.11
Pretreatment nausea in cancer chemotherapy: a conditioned response? Psychosom Med (1980) 1.08
Adrenergic function in patients with panic anxiety. Arch Gen Psychiatry (1984) 1.01
Evolution and the origins of disease. Sci Am (1998) 1.00
Respiratory psychophysiology and anxiety: cognitive intervention in the doxapram model of panic. Psychosom Med (1996) 0.96
Ages of onset of DSM-III anxiety disorders. Compr Psychiatry (1985) 0.91
Effect of alcohol on social phobic anxiety. Am J Psychiatry (1999) 0.90
Peripheral catecholamine levels and the symptoms of anxiety: studies in patients with and without pheochromocytoma. Psychosom Med (1990) 0.90
Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry (1991) 0.88
Cholecystokinin-4 and panic. Arch Gen Psychiatry (1990) 0.86
Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology. Biol Psychiatry (1994) 0.85
Alcohol abuse among clinically anxious patients. Behav Res Ther (1986) 0.84
Endocrine and cardiovascular responses during phobic anxiety. Psychosom Med (1985) 0.83
A comparison of panic disorder and agoraphobia with panic attacks. Compr Psychiatry (1985) 0.83
Anxiety and cardiovascular reactivity in the Tecumseh population. J Hypertens (1998) 0.82
Defense mechanism changes in successfully treated patients with obsessive-compulsive disorder. Am J Psychiatry (1998) 0.82
Group behavioral therapy of obsessive-compulsive disorder: seven vs. twelve-week outcomes. Depress Anxiety (2001) 0.82
Neuroendocrine responses to laboratory panic: cognitive intervention in the doxapram model. Psychoneuroendocrinology (1996) 0.81
Systemic hormonal and physiological abnormalities in anxiety disorders. Psychoneuroendocrinology (1988) 0.80
Urinary catecholamines and mitral valve prolapse in panic-anxiety patients. Psychiatry Res (1985) 0.80
A standardized behavioral group treatment program for obsessive-compulsive disorder: preliminary outcomes. Behav Res Ther (1991) 0.80
Anxiety induced by flooding therapy for phobias does not elicit prolactin secretory response. Psychosom Med (1980) 0.78
Case histories and shorter communications. Agoraphobia: a test of the separation anxiety hypothesis. Behav Res Ther (1985) 0.78
An evolutionary perspective on psychiatry. Compr Psychiatry (1985) 0.77
Platelet alpha 2-adrenoreceptors, catecholamines, hemodynamic variables, and anxiety in panic patients and their asymptomatic relatives. Psychosom Med (1996) 0.76
Treatment of panic-like attacks with a long-acting analogue of somatostatin. J Clin Psychopharmacol (1990) 0.76
Anxiety in patients with pheochromocytomas. Arch Intern Med (1985) 0.76
Evolutionary biology: a basic science for psychiatry? Acta Psychiatr Scand (1992) 0.76
Psychobiology of anxiety and anxiety disorders. Psychiatr Clin North Am (1985) 0.75
Phobic anxiety does not affect plasma levels of thyroid stimulating hormone in man. Psychoneuroendocrinology (1982) 0.75
Symptom profiles of patients with DSM-III anxiety disorders. Am J Psychiatry (1986) 0.75
Panic disorder: a test of the separation anxiety hypothesis. Behav Res Ther (1986) 0.75
Endocrine, cardiovascular, and behavioral responses to clonidine in patients with panic disorder. Biol Psychiatry (1992) 0.75
Stimulation of corticotropin release by pentagastrin in normal subjects and patients with panic disorder. Biol Psychiatry (1991) 0.75
How antipanic drugs might work. Am J Psychiatry (1986) 0.75
Pseudohallucinations in cancer chemotherapy patients. Am J Psychiatry (1983) 0.75
Platelet alpha 2-adrenergic receptor binding and plasma catecholamines. Before and during imipramine treatment in patients with panic anxiety. Arch Gen Psychiatry (1984) 0.75
The dexamethasone suppression test in panic disorder and agoraphobia. Am J Psychiatry (1982) 0.75